石药进军AD百亿蓝海,直指卫材/渤健!恒瑞、先声等群雄逐鹿

医药经济报
Sep 25

阿尔兹海默病(AD)百亿赛道烽烟再起,卫材与渤健将面对石药这位强劲对手,国内外诸多企业也接踵而至加入新一轮的竞逐。9月25日,石药集团发布公告,其开发的仑卡奈单抗注射液获得国家药监局批准,可在中国开展临床试验。该产品按照治疗用生物制品3.3类申报,适用于治疗由AD引起的轻度认知障碍和AD轻度痴呆。值得注意的是,该药为国内首个获得临床许可的仑卡奈单抗注射液生物类似药。AD领域的市场需求一直以来都吸引...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10